2. Search Result
Search Result
Results for "

joint cartilage

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

1

Screening Libraries

1

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-160822
    AGG-523

    PF-5212371

    		 ADAMTS MMP Inflammation/Immunology
    AGG-523 (PF-5212371) is an orally active, reversible, non-hydroxamate, zinc-binding selective inhibitor of ADAMTS4 and ADAMTS5 with IC50 of <0.03 and 0.04 μM. AGG-523 also inhibits MMP-2, -8, 12 activity AGG-523 attenuates release of aggrecanase-generated ARG-aggrecan fragments into synovial fluid, reduces surgery-induced ARG-aggrecan release in rat joint models, and inhibits aggrecanase activity to slow cartilage degradation. AGG-523 can be used for the research of osteoarthritis .
    AGG-523
  • HY-107939
    Paramethasone Acetate

    		Glucocorticoid Receptor Cytochrome P450 Neurological Disease Metabolic Disease Inflammation/Immunology
    Paramethasone Acetate is an orally active long-acting glucocorticoid. Paramethasone Acetate directly inhibits testicular aromatase, thereby reducing the synthesis of estradiol. Paramethasone Acetate suppresses the basal and midcycle luteinizing hormone surges in female animals and blocks estrogen synthesis. Paramethasone Acetate also decreases circulating levels of dihydrotestosterone, androstenedione and estradiol in male animals. Paramethasone Acetate inhibits cartilage degeneration and alleviates joint pathological damage in osteoarthritis models. Paramethasone Acetate can be used in research related to osteoarthritis and endocrinology .
    Paramethasone Acetate
  • HY-178465
    EP4 receptor antagonist 8

    		Prostaglandin Receptor Interleukin Related Neurological Disease Inflammation/Immunology
    EP4 receptor antagonist 8 is an orally active EP4 antagonist (human EP4 IC50 = 6.40 nM). EP4 receptor antagonist 8 significantly reduced paw and joint swelling, inflammatory cell infiltration, cartilage damage, pannus formation, and joint bone erosion in arthritis (AIA) mice in a dose-dependent manner. EP4 receptor antagonist 8 can be used for the study of inflammatory pain .
    EP4 receptor antagonist 8
  • HY-A0179
    Paramethasone

    		Glucocorticoid Receptor Cytochrome P450 Neurological Disease Metabolic Disease Inflammation/Immunology
    Paramethasone is an orally active long-acting glucocorticoid. Paramethasone directly inhibits testicular aromatase, thereby reducing the synthesis of estradiol. Paramethasone suppresses the basal and midcycle luteinizing hormone surges in female animals and blocks estrogen synthesis. Paramethasone also decreases circulating levels of dihydrotestosterone, androstenedione and estradiol in male animals. Paramethasone inhibits cartilage degeneration and alleviates joint pathological damage in osteoarthritis models. Paramethasone can be used in research related to osteoarthritis and endocrinology .
    Paramethasone
  • HY-107939R
    Paramethasone Acetate (Standard)

    		Glucocorticoid Receptor Reference Standards Cytochrome P450 Neurological Disease Metabolic Disease Inflammation/Immunology
    Paramethasone Acetate (Standard) is the analytical standard of Paramethasone Acetate (HY-107939). This product is intended for research and analytical applications. Paramethasone Acetate is an orally active long-acting glucocorticoid. Paramethasone Acetate directly inhibits testicular aromatase, thereby reducing the synthesis of estradiol. Paramethasone Acetate suppresses the basal and midcycle luteinizing hormone surges in female animals and blocks estrogen synthesis. Paramethasone Acetate also decreases circulating levels of dihydrotestosterone, androstenedione and estradiol in male animals. Paramethasone Acetate inhibits cartilage degeneration and alleviates joint pathological damage in osteoarthritis models. Paramethasone Acetate can be used in research related to osteoarthritis and endocrinology.
    Paramethasone Acetate (Standard)
  • HY-P992358
    GSK2394002

    		ADAMTS Cardiovascular Disease
    GSK2394002 is an antibody inhibitor targeting ADAMTS-4 and ADAMTS-5, with cartilage-penetrating ability following systemic administration. GSK2394002 inhibits the release of aggrecan-derived neoepitopes and reduces cartilage degradation, exhibiting the potential to relieve pain, alleviate hyperalgesia and inhibit the progression of joint damage. GSK2394002 also induces potentially irreversible cardiovascular effects such as increased mean arterial pressure and myocardial ischemia in cynomolgus monkeys .
    GSK2394002
  • HY-182884
    TNF-α-IN-29

    		TNF Receptor Inflammation/Immunology
    TNF-α-IN-29 is an orally active and selective TNF-α inhibitor, with IC50 values of 123.0 nM against human targets, and a human Kd of 45.9 nM. TNF-α-IN-29 blocks TNF-α-TNFR1 protein-protein interactions and inhibits TNF-α-mediated inflammatory signaling pathways. TNF-α-IN-29 exhibits anti-inflammatory effects in a mouse model of collagen-induced arthritis and promotes articular cartilage repair. TNF-α-IN-29 can be used for the research of rheumatoid arthritis .
    TNF-α-IN-29

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: